Nothing Special   »   [go: up one dir, main page]

UY39191A - Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas - Google Patents

Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas

Info

Publication number
UY39191A
UY39191A UY0001039191A UY39191A UY39191A UY 39191 A UY39191 A UY 39191A UY 0001039191 A UY0001039191 A UY 0001039191A UY 39191 A UY39191 A UY 39191A UY 39191 A UY39191 A UY 39191A
Authority
UY
Uruguay
Prior art keywords
heavy chain
constant regions
antibodies
multispecific
chain constant
Prior art date
Application number
UY0001039191A
Other languages
English (en)
Inventor
Nathan Trinklein
Katherine Harris
Ute Schellenberger
Omid Vafa
Van Schooten Wim
Force Aldred Shelley
Duy Pham
Starlynn Clarke
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of UY39191A publication Critical patent/UY39191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan anticuerpos multiespecíficos humanos de cadena pesada (p. ej., UniAbsTM) que tienen regiones constantes de cadena pesada modificadas que imparten propiedades ventajosas. La invención se refiere además a métodos para preparar dichos anticuerpos, composiciones, incluidas composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión de una o más de las dianas de unión descritas en la presente.
UY0001039191A 2020-04-29 2021-04-29 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas UY39191A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017589P 2020-04-29 2020-04-29
US202063108796P 2020-11-02 2020-11-02

Publications (1)

Publication Number Publication Date
UY39191A true UY39191A (es) 2021-11-30

Family

ID=76159995

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039191A UY39191A (es) 2020-04-29 2021-04-29 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas

Country Status (8)

Country Link
AR (1) AR127513A2 (es)
CA (1) CA3214992A1 (es)
CL (1) CL2022002963A1 (es)
EC (2) ECSP22083174A (es)
TW (2) TWI838621B (es)
UY (1) UY39191A (es)
WO (1) WO2021222578A1 (es)
ZA (1) ZA202211667B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
ES2980623T3 (es) 2016-09-14 2024-10-02 Teneoone Inc Anticuerpos de unión a CD3
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
SG11202005880XA (en) 2017-12-22 2020-07-29 Teneobio Inc Heavy chain antibodies binding to cd22
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
CN118019763A (zh) * 2021-08-09 2024-05-10 和铂医药(上海)有限责任公司 靶向cldn18.2的抗体、双特异性抗体及其应用
TW202430553A (zh) 2022-11-24 2024-08-01 中國大陸商上海藥明生物技術有限公司 Psma抗體及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
EP1362061A2 (en) 2001-02-20 2003-11-19 ZymoGenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
NZ538996A (en) 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
PE20151807A1 (es) * 2013-04-29 2015-12-02 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
HUE050556T2 (hu) * 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
SG11201805770UA (en) * 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
BR112019002579A2 (pt) * 2016-08-16 2019-05-21 Epimab Biotherapeutics, Inc. anticorpos biespecíficos fab monovalentes, assimétricos e tandem
ES2980623T3 (es) * 2016-09-14 2024-10-02 Teneoone Inc Anticuerpos de unión a CD3
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20200049757A (ko) 2017-06-30 2020-05-08 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체
WO2019074973A2 (en) * 2017-10-10 2019-04-18 Sanofi ANTI-CD38 ANTIBODIES AND METHODS OF USE
CN112351997B (zh) 2018-07-20 2023-05-26 坦尼奥第二公司 与cd19结合的重链抗体
WO2020061478A2 (en) * 2018-09-21 2020-03-26 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies

Also Published As

Publication number Publication date
ECSP22083174A (es) 2022-11-30
ECSP23025065A (es) 2023-06-30
CL2022002963A1 (es) 2023-06-30
TW202206462A (zh) 2022-02-16
WO2021222578A1 (en) 2021-11-04
TW202330622A (zh) 2023-08-01
AR127513A2 (es) 2024-01-31
TWI838621B (zh) 2024-04-11
CA3214992A1 (en) 2021-11-04
ZA202211667B (en) 2023-10-25

Similar Documents

Publication Publication Date Title
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2022002963A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
BR112019006106A2 (pt) formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio.
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
CO2020008925A2 (es) Anticuerpos de cadena pesada que se unen a cd22
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
UY39715A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
CO2023000808A2 (es) Unión de anticuerpos multiespecíficos a bcma
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
UY39522A (es) Anticuerpos de cadena pesada que se unen al receptor alfa de folato
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
CO2022015105A2 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2023002284A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
AR122120A1 (es) Moléculas de fijación para el tratamiento de cáncer
CL2022002404A1 (es) Anticuerpos anti-gitr y usos de estos
AR106572A1 (es) Inhibidores de asgr